Drugs / NEZASTOMIG
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06826768 | Jul 2025 → May 2027 expected | prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06085664 | Dec 2023 → Jun 2028 expected | prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05125016 | Nov 2021 → Mar 2030 expected | castration-resistant prostate carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03972657 | Aug 2019 → Nov 2027 expected | castration-resistant prostate carcinoma, clear cell renal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEZASTOMIG | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594597 ↗ |
| Known as | REGN5678 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06826768 ↗ |
| Modality | Monoclonal antibody | “REGN5678 (a PSMAxCD28 Bispecific Antibody)” NCT05125016 ↗ |
| Route | Intravenous | “Given by IV (vein)” NCT06085664 ↗ |